{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T15:07:24Z","timestamp":1722611244937},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2009,1,14]],"date-time":"2009-01-14T00:00:00Z","timestamp":1231891200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1007\/s00115-008-2631-y","type":"journal-article","created":{"date-parts":[[2009,1,12]],"date-time":"2009-01-12T18:40:21Z","timestamp":1231785621000},"page":"678-687","source":"Crossref","is-referenced-by-count":12,"title":["Bedeutung intraven\u00f6ser Immunglobuline zur Behandlung immunvermittelter Polyneuropathien","The significance of intravenous immunoglobulin in treatment of immune-mediated polyneuropathies"],"prefix":"10.1007","volume":"80","author":[{"given":"M.","family":"Stangel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.-P.","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Gold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.C.","family":"Kieseier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,1,14]]},"reference":[{"key":"2631_CR1","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/01.wco.0000245365.51823.72","volume":"19","author":"Kieseier","year":"2006","unstructured":"Kieseier BC, Hartung HP, Wiendl H (2006) Immune circuitry in the peripheral nervous system. Curr Opin Neurol 19:437\u2013445","journal-title":"Curr Opin Neurol"},{"key":"2631_CR2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/mus.20893","volume":"37","author":"Meyer","year":"2008","unstructured":"Meyer zu Horste G, Hu W, Hartung HP et al (2008) The immunocompetence of schwann cells. Muscle Nerve 37:3\u201313","journal-title":"Muscle Nerve"},{"key":"2631_CR3","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/01.wco.0000245364.51823.3b","volume":"19","author":"Kieseier","year":"2006","unstructured":"Kieseier BC, Wiendl H, Hartung HP (2006) The inflamed peripheral nervous system: update on immune therapies. Curr Opin Neurol 19:433\u2013436","journal-title":"Curr Opin Neurol"},{"key":"2631_CR4","doi-asserted-by":"crossref","first-page":"V59","DOI":"10.1007\/s00415-006-5008-9","volume":"253","author":"Gold","year":"2006","unstructured":"Gold R, Kieseier BC (2006) Therapy of immune neuropathies with intravenous immunoglobulins. J Neurol 253:V59\u2013V63","journal-title":"J Neurol"},{"key":"2631_CR5","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/ncpneuro0452","volume":"3","author":"Meyer","year":"2007","unstructured":"Meyer zu Horste G, Hartung HP, Kieseier BC (2007) From bench to bedside\u2013experimental rationale for immune-specific therapies in the inflamed peripheral nerve. Nat Clin Pract Neurol 3:198\u2013211","journal-title":"Nat Clin Pract Neurol"},{"key":"2631_CR6","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/00019052-200210000-00013","volume":"15","author":"M\u00e4urer","year":"2002","unstructured":"M\u00e4urer M, Gold R (2002) Animal models of immune-mediated neuropathies. Curr Opin Neurol 15:617\u2013622","journal-title":"Curr Opin Neurol"},{"key":"2631_CR7","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1212\/WNL.56.1.74","volume":"56","author":"Bosboom","year":"2001","unstructured":"Bosboom WM, Van den Berg LH, Mollee I et al (2001) Sural nerve T-cell receptor Vbeta gene utilization in chronic inflammatory demyelinating polyneuropathy and vasculitic neuropathy. Neurology 56:74\u201381","journal-title":"Neurology"},{"key":"2631_CR8","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.4049\/jimmunol.164.8.4375","volume":"164","author":"Illes","year":"2000","unstructured":"Illes Z, Kondo T, Newcombe J et al (2000) Differential expression of NK T cell V alpha 24J alpha Q invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. J Immunol 164:4375\u20134381","journal-title":"J Immunol"},{"key":"2631_CR9","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/(SICI)1097-4598(199604)19:4<474::AID-MUS8>3.0.CO;2-9","volume":"19","author":"Schmidt","year":"1996","unstructured":"Schmidt B, Toyka KV, Kiefer R et al (1996) Inflammatory infiltrates in sural nerve biopsies in Guillain-Barr\u00e9 syndrome and chronic inflammatory demyelinating neuropathy. Muscle Nerve 19:474\u2013487","journal-title":"Muscle Nerve"},{"key":"2631_CR10","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/s004150200072","volume":"249","author":"Winer","year":"2002","unstructured":"Winer J, Hughes S, Cooper J et al (2002) gammadelta T cells infiltrating sensory nerve biopsies from patients with inflammatory neuropathy. J Neurol 249:616\u2013621","journal-title":"J Neurol"},{"key":"2631_CR11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/intimm\/dxh018","volume":"16","author":"Illes","year":"2004","unstructured":"Illes Z, Shimamura M, Newcombe J et al (2004) Accumulation of Valpha7.2-Jalpha33 invariant T cells in human autoimmune inflammatory lesions in the nervous system. Int Immunol 16:223\u2013230","journal-title":"Int Immunol"},{"key":"2631_CR12","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0165-5728(03)00212-1","volume":"141","author":"Koga","year":"2003","unstructured":"Koga M, Yuki N, Tsukada Y et al (2003) CDR3 spectratyping analysis of the T cell receptor repertoire in Guillain-Barre and Fisher syndromes. J Neuroimmunol 141:112\u2013117","journal-title":"J Neuroimmunol"},{"key":"2631_CR13","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1750-3639.1999.tb00231.x","volume":"9","author":"Gold","year":"1999","unstructured":"Gold R, Archelos JJ, Hartung H-P (1999) Mechanisms of immune regulation in the peripheral nervous system. Brain Pathol 9:343\u2013360","journal-title":"Brain Pathol"},{"key":"2631_CR14","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/00005072-199311000-00001","volume":"52","author":"Griffin","year":"1993","unstructured":"Griffin JW, George R, Ho T (1993) Macrophage systems in peripheral nerves. A review. J Neuropathol Exp Neurol 52:553\u2013560","journal-title":"J Neuropathol Exp Neurol"},{"key":"2631_CR15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0301-0082(00)00060-5","volume":"64","author":"Kiefer","year":"2001","unstructured":"Kiefer R, Kieseier BC, Stoll G et al (2001) The role of macrophages in immune-mediated damage to the peripheral nervous system. Prog Neurobiol 64:109\u2013127","journal-title":"Prog Neurobiol"},{"key":"2631_CR16","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/mus.20076","volume":"30","author":"Kieseier","year":"2004","unstructured":"Kieseier BC, Kiefer R, Gold R et al (2004) Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 30:131\u2013156","journal-title":"Muscle Nerve"},{"key":"2631_CR17","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1093\/brain\/awf272","volume":"125","author":"Willison","year":"2002","unstructured":"Willison HJ, Yuki N (2002) Peripheral neuropathies and anti-glycolipid antibodies. Brain 125:2591\u20132625","journal-title":"Brain"},{"key":"2631_CR18","doi-asserted-by":"crossref","first-page":"11404","DOI":"10.1073\/pnas.0402391101","volume":"101","author":"Yuki","year":"2004","unstructured":"Yuki N, Susuki K, Koga M et al (2004) Carbohydrate mimicry between human ganglioside GM1 and campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. Proc Natl Acad Sci U S A 101:11404\u201311409","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2631_CR19","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/ana.1012","volume":"49","author":"Yuki","year":"2001","unstructured":"Yuki N, Yamada M, Koga M et al (2001) Animal model of axonal Guillain-Barr\u00e9 syndrome induced by sensitization with GM1 ganliosides. Ann Neurol 49:712\u2013720","journal-title":"Ann Neurol"},{"key":"2631_CR20","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/00019052-200210000-00008","volume":"15","author":"Hartung","year":"2002","unstructured":"Hartung H-P, Willison H, Kieseier BC (2002) Acute immunoinflammatory neuropathy: Update on Guillain-Barr\u00e9 Syndrome. Curr Opin Neurol 15:571\u2013577","journal-title":"Curr Opin Neurol"},{"key":"2631_CR21","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/brain\/awm316","volume":"131","author":"Halstead","year":"2008","unstructured":"Halstead SK, Zitman FM, Humphreys PD et al (2008) Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 131:1197\u20131208","journal-title":"Brain"},{"key":"2631_CR22","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1093\/brain\/awg235","volume":"126","author":"Jacobs","year":"2003","unstructured":"Jacobs BC, O\u2019Hanlon GM, Bullens RW et al (2003) Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain 126:2220\u20132234","journal-title":"Brain"},{"key":"2631_CR23","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1460-9568.1998.00053.x","volume":"10","author":"Buchwald","year":"1998","unstructured":"Buchwald B, Weishaupt A, Toyka KV et al (1998) Pre- and postsynaptic blockade of neuromuscular transmission by Miller-Fisher syndrome IgG at mouse motor nerve terminals. Eur J Neurosci 10:281\u2013290","journal-title":"Eur J Neurosci"},{"key":"2631_CR24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0165-5728(03)00156-5","volume":"139","author":"Dilley","year":"2003","unstructured":"Dilley A, Gregson NA, Hadden RD et al (2003) Effects on axonal conduction of anti-ganglioside sera and sera from patients with Guillain-Barre syndrome. J Neuroimmunol 139:133\u2013140","journal-title":"J Neuroimmunol"},{"key":"2631_CR25","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/mus.10349","volume":"27","author":"Krampfl","year":"2003","unstructured":"Krampfl K, Mohammadi B, Buchwald B et al (2003) IgG from patients with Guillain-Barre syndrome interact with nicotinic acetylcholine receptor channels. Muscle Nerve 27:435\u2013441","journal-title":"Muscle Nerve"},{"key":"2631_CR26","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.autrev.2006.08.011","volume":"6","author":"Katz","year":"2007","unstructured":"Katz U, Achiron A, Sherer Y et al (2007) Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 6:257\u2013259","journal-title":"Autoimmun Rev"},{"key":"2631_CR27","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7326\/0003-4819-126-9-199705010-00008","volume":"126","author":"Dalakas","year":"1997","unstructured":"Dalakas MC (1997) Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med 126:721\u2013730","journal-title":"Ann Intern Med"},{"key":"2631_CR28","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/ncpneuro0376","volume":"3","author":"Gold","year":"2007","unstructured":"Gold R, Stangel M, Dalakas MC (2007) Drug Insight: the use of intravenous immunoglobulin in neurology\u2013therapeutic considerations and practical issues. Nat Clin Pract Neurol 3:36\u201344","journal-title":"Nat Clin Pract Neurol"},{"key":"2631_CR29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.transci.2007.01.012","volume":"37","author":"Siberil","year":"2007","unstructured":"Siberil S, SriRamulu E, Vir-Singh N et al (2007) Intravenous immunoglobulin in autoimmune and inflammatory diseases: more than mere transfer of antibodies. Transfus Apher Sci 37:103\u2013107","journal-title":"Transfus Apher Sci"},{"key":"2631_CR30","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1126\/science.1129594","volume":"313","author":"Kaneko","year":"2006","unstructured":"Kaneko Y, Nimmerjahn F, Ravetch JV (2006) Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313(5787):670\u2013673","journal-title":"Science"},{"key":"2631_CR31","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1074-7613(03)00080-3","volume":"18","author":"Bruhns","year":"2003","unstructured":"Bruhns P, Samuelsson A, Pollard JW, Ravetch JV (2003) Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 18:573\u2013581","journal-title":"Immunity"},{"key":"2631_CR32","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev.immunol.26.021607.090232","volume":"26","author":"Nimmerjahn","year":"2008","unstructured":"Nimmerjahn F, Ravetch JV (2008) Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 26:513\u2013533 Review","journal-title":"Annu Rev Immunol"},{"key":"2631_CR33","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1212\/WNL.46.1.100","volume":"46","author":"Bril","year":"1996","unstructured":"Bril V, Ilse WK, Pearce R et al (1996) Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barre syndrome. Neurology 46:100\u2013103","journal-title":"Neurology"},{"key":"2631_CR34","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","volume":"349","author":"Plasma","year":"1997","unstructured":"Plasma, Exchange\/Sandoglobulin, Guillain-Barr\u00e9 et al (1997) Randomised trial of plasma exchange, intravenous immuoglobulin and combined treatments in Guillain-Barr\u00e9 syndrome. Lancet 349:225\u2013230","journal-title":"Lancet"},{"key":"2631_CR35","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","volume":"326","author":"van","year":"1992","unstructured":"van der Mech\u00e9 FG, Schmitz PI (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med 326:1123\u20131129","journal-title":"N Engl J Med"},{"key":"2631_CR36","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000050777","volume":"46","author":"Diener","year":"2001","unstructured":"Diener HC, Haupt WF, Kloss TM et al (2001) A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange and immune adsorption in Guillain-Barre syndrome. Eur Neurol 46:107\u2013109","journal-title":"Eur Neurol"},{"key":"2631_CR37","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1744-9987.1998.tb00124.x","volume":"2","author":"Hosokawa","year":"1998","unstructured":"Hosokawa T, Hamaguchi K, Tomioka R et al (1998) Comparative study of efficacy of plasma exchange versus intravenous gammaglobulin treatment on acute postinfectious polyradiculoneuropathy: a preliminary report. Ther Apher Dial 2:288\u2013291","journal-title":"Ther Apher Dial"},{"key":"2631_CR38","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1093\/brain\/awm004","volume":"130","author":"Hughes","year":"2007","unstructured":"Hughes RA, Swan AV, Raphael JC et al (2007) Immunotherapy for Guillain-Barre syndrome: a systematic review. Brain 130:2245\u20132257","journal-title":"Brain"},{"key":"2631_CR39","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","volume":"1","author":"Imbach","year":"1981","unstructured":"Imbach P, Barandun S, d\u2019Apuzzo V et al (1981) High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1:1228\u20131231","journal-title":"Lancet"},{"key":"2631_CR40","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/jnnp.71.2.235","volume":"71","author":"Raphael","year":"2001","unstructured":"Raphael JC, Chevret S, Harboun M et al (2001) Intravenous immune globulins in patients with Guillain-Barre syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry 71:235\u2013238","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2631_CR41","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1542\/peds.2004-1324","volume":"116","author":"Korinthenberg","year":"2005","unstructured":"Korinthenberg R, Schessl J, Kirschner J et al (2005) Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barre syndrome: a randomized trial. Pediatrics 116:8\u201314","journal-title":"Pediatrics"},{"key":"2631_CR42","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/brain\/118.4.841","volume":"118","author":"Visser","year":"1995","unstructured":"Visser LH, Van der Meche FG, Van Doorn PA et al (1995) Guillain-Barre syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain-Barre Study Group. Brain 118:841\u2013847","journal-title":"Brain"},{"key":"2631_CR43","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/1531-8249(200003)47:3<314::AID-ANA6>3.0.CO;2-C","volume":"47","author":"Yuki","year":"2000","unstructured":"Yuki N, Ang CW, Koga M et al (2000) Clinical features and response to treatment in Guillain-Barre syndrome associated with antibodies to GM1b ganglioside. Ann Neurol 47:314\u2013321","journal-title":"Ann Neurol"},{"key":"2631_CR44","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ana.410400209","volume":"40","author":"Jacobs","year":"1996","unstructured":"Jacobs BC, van Doorn PA, Schmitz PI et al (1996) Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barre syndrome. Ann Neurol 40:181\u2013187","journal-title":"Ann Neurol"},{"key":"2631_CR45","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1212\/WNL.56.6.758","volume":"56","author":"Hadden","year":"2001","unstructured":"Hadden RD, Karch H, Hartung HP et al (2001) Preceding infections, immune factors and outcome in Guillain-Barre syndrome. Neurology 56:758\u2013765","journal-title":"Neurology"},{"key":"2631_CR46","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0140-6736(03)15324-X","volume":"363","author":"van","year":"2004","unstructured":"van Koningsveld R, Schmitz PI, Meche FG et al (2004) Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome: randomised trial. Lancet 363:192\u2013196","journal-title":"Lancet"},{"key":"2631_CR47","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00115-004-1733-4","volume":"75","author":"Stangel","year":"2004","unstructured":"Stangel M, Gold R, Einsatz von i.v (2004) Immunglobulinen in der Neurologie. Nervenarzt 75:801\u2013815","journal-title":"Nervenarzt"},{"key":"2631_CR48","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/WCO.0b013e3282ff5b8f","volume":"21","author":"Linker","year":"2008","unstructured":"Linker RA, Gold R (2008) Use of intravenous immunoglobulin and plasma exchange in neurological disease. Curr Opin Neurol 21:358\u2013365","journal-title":"Curr Opin Neurol"},{"key":"2631_CR49","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMra041347","volume":"352","author":"K\u00f6ller","year":"2005","unstructured":"K\u00f6ller H, Kieseier BC, Jander S, Hartung HP (2005) Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 352:1343\u20131356","journal-title":"N Engl J Med"},{"key":"2631_CR50","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1212\/WNL.40.2.209","volume":"40","author":"Doorn","year":"1990","unstructured":"Doorn P van, Brand A, Strengers P et al (1990) High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology 40:209\u2013212","journal-title":"Neurology"},{"key":"2631_CR51","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/brain\/119.4.1067","volume":"119","author":"Hahn","year":"1996","unstructured":"Hahn AF, Bolton CF, Zochodne D et al (1996) Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 119:1067\u20131077","journal-title":"Brain"},{"key":"2631_CR52","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/ana.410300119","volume":"30","author":"Cornblath","year":"1991","unstructured":"Cornblath DR, Chaudry V, Griffin JW (1991) Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Ann Neurol 30:104\u2013106","journal-title":"Ann Neurol"},{"key":"2631_CR53","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1474-4422(02)00222-3","volume":"1","author":"Schaik","year":"2002","unstructured":"Schaik IN van, Winer JB, Haan R de et al (2002) Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review. Lancet Neurol 1:491\u2013498","journal-title":"Lancet Neurol"},{"key":"2631_CR54","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/brain\/119.4.1055","volume":"119","author":"Hahn","year":"1996","unstructured":"Hahn AF, Bolton CF, Pillay N et al (1996) Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 119(Pt 4):1055\u20131066","journal-title":"Brain"},{"key":"2631_CR55","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1212\/WNL.56.4.445","volume":"56","author":"Mendell","year":"2001","unstructured":"Mendell JR, J BR, Freimer ML et al (2001) Randomized controlled trial of IVIg in untreated chronic inflammatory demeylinating polyradiculoneuropathy. Neurology 56:445\u2013449","journal-title":"Neurology"},{"key":"2631_CR56","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ana.1088","volume":"50","author":"Hughes","year":"2001","unstructured":"Hughes R, Bensa S, Willison H et al (2001) Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculopathy. Ann Neurol 50:195\u2013201","journal-title":"Ann Neurol"},{"key":"2631_CR57","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1085-9489.2005.10302.x","volume":"10","author":"European","year":"2005","unstructured":"European Federation of Neurological Societies, Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy (2005) Report of a joint task force of the European federation of neurological societies and the peripheral nerve society. J Peripher Nerv Syst 10:220\u2013228","journal-title":"J Peripher Nerv Syst"},{"key":"2631_CR58","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","volume":"7","author":"Hughes","year":"2008","unstructured":"Hughes RA, Donofrio P, Bril V et al (2008) Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 7:136\u2013144","journal-title":"Lancet Neurol"},{"key":"2631_CR59","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1212\/WNL.60.8_suppl_3.S8","volume":"60","author":"Sander","year":"2003","unstructured":"Sander HW, Latov N (2003) Research criteria for defining patients with CIDP. Neurology 60:S8\u2013S15","journal-title":"Neurology"},{"key":"2631_CR60","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1474-4422(07)70330-7","volume":"7","author":"Vermeulen","year":"2008","unstructured":"Vermeulen M (2008) Intravenous immunoglobulin: a first-line treatment in CIDP? Lancet Neurol 7:115\u2013116","journal-title":"Lancet Neurol"},{"key":"2631_CR61","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/jnnp.56.1.36","volume":"56","author":"Vermeulen","year":"1993","unstructured":"Vermeulen M, Doorn PA van, Brand A et al (1993) Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 56:36\u201339","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2631_CR62","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/BF00868527","volume":"243","author":"Thompson","year":"1996","unstructured":"Thompson N, Choudhary P, Hughes RA, Quinlivan RM (1996) A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol 243:280\u2013285","journal-title":"J Neurol"},{"key":"2631_CR63","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1474-4422(05)70074-0","volume":"4","author":"Asseldonk","year":"2005","unstructured":"Asseldonk JT Van, Franssen H, Berg-Vos RM Van den et al (2005) Multifocal motor neuropathy. Lancet Neurol 4:309\u2013319","journal-title":"Lancet Neurol"},{"key":"2631_CR64","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1212\/WNL.44.3_Part_1.429","volume":"44","author":"Azulay","year":"1994","unstructured":"Azulay JP, Blin O, Pouget J et al (1994) Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology 44:429\u2013432","journal-title":"Neurology"},{"key":"2631_CR65","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1212\/WNL.55.9.1256","volume":"55","author":"Federico","year":"2000","unstructured":"Federico P, Zochodne DW, Hahn AF et al (2000) Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 55:1256\u20131262","journal-title":"Neurology"},{"key":"2631_CR66","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/brain\/124.1.145","volume":"124","author":"Leger","year":"2001","unstructured":"Leger JM, Chassande B, Musset L et al (2001) Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 124:145\u2013153","journal-title":"Brain"},{"key":"2631_CR67","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1136\/jnnp.59.3.248","volume":"59","author":"Berg","year":"1995","unstructured":"Berg LH Van den, Kerkhoff H, Oey PL et al (1995) Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 59:248\u2013252","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2631_CR68","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/1531-8249(200012)48:6<919::AID-ANA13>3.0.CO;2-J","volume":"48","author":"Berg-Vos","year":"2000","unstructured":"Berg-Vos RM Van den, Franssen H, Wokke JH et al (2000) Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin treatment. Ann Neurol 48:919\u2013926","journal-title":"Ann Neurol"},{"key":"2631_CR69","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/jnnp.72.6.761","volume":"72","author":"Nobile-Orazio","year":"2002","unstructured":"Nobile-Orazio E, Cappellari A, Meucci N et al (2002) Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block. J Neurol Neurosurg Psychiatry 72:761\u2013766","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2631_CR70","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/jnnp.67.1.15","volume":"67","author":"Ellis","year":"1999","unstructured":"Ellis CM, Leary S, Payan J et al (1999) Use of human intravenous immunoglobulin in lower motor neuron syndromes. J Neurol Neurosurg Psychiatry 67:15\u201319","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2631_CR71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1085-9489.2006.00058.x","volume":"11","author":"Joint","year":"2006","unstructured":"Joint Task Force of the EFNS and the PNS (2006) European federation of neurological societies \/ peripheral nerve society guideline on management of multifocal motor neuropathy. Report of a joint task force of the european federation of neurological societies and the peripheral nerve society. J Peripher Nerv Syst 11:1\u20138","journal-title":"J Peripher Nerv Syst"},{"key":"2631_CR72","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1136\/jnnp.2007.121756","volume":"79","author":"Leger","year":"2008","unstructured":"Leger JM, Viala K, Cancalon F et al (2008) Intravenous immunoglobulin as short- and long-term therapy of multifocal motor neuropathy: a retrospective study of response to IVIg and of its predictive criteria in 40 patients. J Neurol Neurosurg Psychiatry 79:93\u201396","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2631_CR73","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1212\/01.WNL.0000110185.23464.A1","volume":"62","author":"Terenghi","year":"2004","unstructured":"Terenghi F, Cappellari A, Bersano A et al (2004) How long is IVIg effective in multifocal motor neuropathy? Neurology 62:666\u2013668","journal-title":"Neurology"},{"key":"2631_CR74","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/WCO.0b013e3282ef79e3","volume":"20","author":"Lozeron","year":"2007","unstructured":"Lozeron P, Adams D (2007) Monoclonal gammopathy and neuropathy. Curr Opin Neurol 20:536\u2013541","journal-title":"Curr Opin Neurol"},{"key":"2631_CR75","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1007\/s00415-002-0808-z","volume":"249","author":"Comi","year":"2002","unstructured":"Comi G, Roveri L, Swan A et al (2002) A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol 249:1370\u20131377","journal-title":"J Neurol"},{"key":"2631_CR76","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1001\/archneur.59.5.766","volume":"59","author":"Gorson","year":"2002","unstructured":"Gorson KC, Ropper AH, Weinberg DH et al (2002) Efficacy of intravenous immunoglobulin in patients with IgG monoclonal gammopathy and polyneuropathy. Arch Neurol 59:766\u2013772","journal-title":"Arch Neurol"},{"key":"2631_CR77","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1085-9489.2006.00059.x","volume":"11","author":"Joint","year":"2006","unstructured":"Joint Task Force of the EFNS and the PNS (2006) European Federation of Neurological Societies \/ Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a joint task force of the European federation of neurological societies and the peripheral nerve society. J Peripher Nerv Syst 11:9\u201319","journal-title":"J Peripher Nerv Syst"},{"key":"2631_CR78","doi-asserted-by":"crossref","unstructured":"Kieseier BC, Meyer zu H\u00f6rste G, Lehmann HC et al (2008) Intravenous immunoglobulins in the treatment of immune neuropathies. Curr Opin Neurol (in press)","DOI":"10.1097\/WCO.0b013e32830efc03"},{"key":"2631_CR79","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s00415-006-0258-0","volume":"253","author":"Koller","year":"2006","unstructured":"Koller H, Schroeter M, Feischen H et al (2006) Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies. J Neurol 253:1505\u20131506","journal-title":"J Neurol"},{"key":"2631_CR80","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/mus.20909","volume":"37","author":"Lee","year":"2008","unstructured":"Lee DH, Linker RA, Paulus W et al (2008) Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 37:406\u2013409","journal-title":"Muscle Nerve"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-008-2631-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-008-2631-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-008-2631-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T20:06:13Z","timestamp":1632945973000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-008-2631-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,14]]},"references-count":80,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["2631"],"URL":"https:\/\/doi.org\/10.1007\/s00115-008-2631-y","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,14]]}}}